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Abstract Salvicine is a novel diterpenoid quinone derivative
possessing strong antitumor activities and was demonstrated to
stabilize the DNA topoisomerase II (Topo II) cleavage complex
in vitro and in vivo. In the present work we investigated the
possible mechanism through which disturbance of Topo II by
salvicine led to cell death. We found that salvicine induced DNA
strand breaks in human promyelocytic leukemia HL-60 cells and
DNA damage correlated with cell growth inhibition. DNA
damage induced by brief exposure to salvicine could be partially
reversed, but early DNA breaks triggered the process of
apoptosis. Preferential damage in the P2 promoter region of
the oncogene c-myc was detected, whereas no obvious DNA
damage was found in the 3P region of the same gene.
Furthermore, the expression of some protooncogenes such as c-
myc, c-fos and c-jun was examined, showing that salvicine
produced a reduction in the transcription rate of c-myc in a dose-
dependent manner and a marked induction of c-fos and c-jun
expression was observed. It appears possible that DNA damage
within such genomic regions is an early event, which could lead to
growth inhibition mediated by alterations of the expression of
selected proliferation regulatory genes, such as c-myc, c-fos and
c-jun, and ultimately cell death. ß 2001 Published by Elsevier
Science B.V. on behalf of the Federation of European Biochem-
ical Societies.
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1. Introduction
Leukemia is one of the most threatening diseases today.
With the recognition that most adult leukemia patients are
not candidates for transplantation, and that a more rational
therapy is not adequately de¢ned, leukemia patients are
treated with regimens that focus on (or at least contain) che-
motherapy. Drugs targeting DNA topoisomerase II (Topo II)
are among the most active and widely prescribed anticancer
agents for the treatment of human leukemia [1]. However, the
nature of the signaling events leading to growth arrest and/or
cell death subsequent to DNA breaks have not been fully
resolved.
Salvicine (4,5-seco-5,10-friedo-abieta-3,4-dihydroxy-5(10),
6,8,13-tetraene-11,12-dione, Fig. 1), a diterpenoid quinone
compound, is a new Topo II inhibitor and induces Topo II-
mediated DNA breaks [2]. It is a structurally modi¢ed deriv-
ative of a natural product from the Chinese traditional herb
Salvia prionitis Hance (Labiatae) [3]. Its pharmaceutical activ-
ity was evaluated against a panel of human tumor cells [2] and
xenografts [5]. Salvicine is equipotent to etoposide against
three leukemia cell lines [4]. Additionally, salvicine has a
prominent cytotoxic e¡ect on multidrug-resistant (MDR)
cell lines with an average resistance factor of 1.2 on three
MDR cell lines, accompanied by a decrease in the expression
of MDR-1 mRNA and P-glycoprotein in MDR tumor cells
(unpublished data of studies in our laboratory). Salvicine, like
most chemotherapeutic drugs, exerts its anti-tumor e¡ect by
inducing cancer cell apoptosis [6], and salvicine is equally
e¡ective at inducing apoptosis in K-562 and K-562/A02 cells.
Considering that both of these cell lines are resistant to apo-
ptosis, salvicine appears to be a very promising antitumor
candidate, and is entering clinical trial in China.
Though the mechanism of salvicine-induced tumor cell apo-
ptosis has not been fully established, it is believed that salvi-
cine acts through trapping the Topo^DNA cleavage complex.
Induction of DNA damage by Topo II inhibitors has been
shown to correspond closely to drug cytotoxicity and/or anti-
proliferative activity [7]. However, the signaling pathways
leading to cell death subsequent to DNA breaks have not
been fully described. Previous work has indicated that Topo
II inhibitors such as VM26 [8], AMSA [9] and more recently
pMC540 [10] induce preferential damage within the c-myc
locus. Another study found that Topo II cleaved c-fos around
the region that possessed enhancer-like properties in a cell-free
system [11]. These ¢ndings suggest that some protooncogenes
may be closely linked with the signal transduction pathway
leading to growth arrest or cell death.
Ampli¢cation of the c-myc gene was observed in the human
promyelocytic leukemia HL-60 cells [12] and was believed to
be critical to the proliferation of this cell line. Previous re-
search indicated that salvicine displayed high cytotoxicity to
HL-60 cells in vitro [4]. It remains unclear whether salvicine
induces damage in the c-myc locus, or if c-myc and other
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protooncogenes are involved in the apoptosis pathway of HL-
60 cells. In this report, we study the in£uence of salvicine on
bulk and gene-speci¢c damage, and its e¡ect on the expression
of c-myc, c-fos and c-jun in HL-60 cells to explore the possible
mechanisms of salvicine-induced apoptosis.
2. Materials and methods
2.1. Chemicals
Salvicine, presenting as a tangerine yellow color crystalloid, was
provided by the Phytochemistry Department of Shanghai Institute
of Materia Medica. 3-(4,5-Dimethyl-2-thiazolyl)-2,5-diphenyl tetrazo-
lium bromide (MTT) and dimethyl sulfoxide (DMSO) were from Sig-
ma Chemical Co; M-MLV reverse transcriptase, RPMI 1640 medium
and TRIzol reagent were from Gibco-BRL. Random hexamers were
from Promega. Salvicine was solubilized at 0.1 M in DMSO as a stock
solution and diluted with normal saline before use. The maximum
¢nal concentration of DMSO, employed as vehicle control, was
0.5% (v/v). All other chemicals were reagent grade.
2.2. Cell culture
The HL-60 promyelocytic leukemia cell line was from American
Type Culture Collection. Cells were maintained in RPMI 1640 me-
dium supplemented with 10% heat-inactivated fetal bovine serum,
2 mM L-glutamine, 100 kIU/l benzylpenicillin, 100 mg/l streptomycin
and 10 mM HEPES (pH 7.4) in a humidi¢ed atmosphere of 95% air
with 5% CO2 at 37‡C.
2.3. Growth inhibition assay
The capacity of salvicine to interfere with the growth of HL-60 cells
was determined using the MTT dye assay [13] with minor modi¢ca-
tions. Brie£y, cells seeded at a density of 5U104 cells/ml in 96-well
microplates were treated with salvicine for 2 h at 37‡C, washed free of
drug with phosphate-bu¡ered saline (PBS, pH 7.4), then incubated
with fresh medium for an additional 72 h. At the end of culture, 20
Wl of MTT (5 mg/ml) was added to each well and the plate was placed
at 37‡C for 4 h; then 100 Wl ‘triplex solution’ (10% SDS^5% isobu-
tanol^12 mM HCl) was added and the cells were incubated at 37‡C
for 12^20 h. The plates were measured by the absorbance at 570 nm
using a multiwell spectrophotometer (VERSAmax, Molecular Devi-
ces, USA). The cytotoxicity of salvicine on tumor cells was expressed
as IC50, which was calculated using the logit method.
2.4. Alkaline unwinding assay
Bulk damage to DNA was determined using the alkaline unwinding
procedure [14]. Exponentially growing cells were exposed to salvicine
for 2 h at 37‡C. Following exposure to the drug, the cells were col-
lected and washed with ice-cold PBS. The cell pellet was then resus-
pended in PBS, and the number of cells was determined prior to
analysis for strand breaks. This assay is based on the di¡erential
binding and £uorescence of bisbenzimide trihydrochloride (Hoechst
33258) to single- and double-strand DNA after a ¢xed period of
alkaline denaturation. Each condition (4.5U106 cells/condition) was
subdivided into three di¡erent groups: (a) double-strand DNA con-
trol, with no alkaline-induced DNA unwinding; (b) cells treated for a
30-min alkaline-induced DNA unwinding period; and (c) total single-
strand DNA, where cells were sonicated before alkaline unwinding.
F values, de¢ned as F = (alkali-treated DNA minus single-strand
DNA)/(double-strand DNA control minus single-strand DNA), were
determined in triplicate.
2.5. Secondary DNA fragmentation assay
Exponentially growing HL-60 cells were treated with 10 WM salvi-
cine for 30 min. Salvicine was removed by washing with PBS three
times, after which cells were further cultured in drug-free medium for
30 min, 1, 2, 3 or 6 h. Total DNA was extracted according to the
procedure of Slin et al. [15]. The DNA samples were subjected to
electrophoresis in a 1.5% agarose gel. The DNA bands was stained
with ethidium bromide and photographed using the GDS8000 Gel
Documentation System (UVP, USA).
2.6. PCR stop assay
HL-60 cells were incubated with salvicine for 30 min, then cells
were washed and resuspended in 100 Wl of lysis bu¡er (50 mM KCl,
10 mM Tris^HCl (pH 9.0), 0.5% Triton X-100, 0.45% Tween-20, 0.06
mg/ml proteinase K). The lysate was incubated at 50‡C for 2 h fol-
lowed by a cycle at 94‡C for 12 min. After centrifugation at 10 000Ug
for 3 min, the supernatant was used for PCR. PCR stop assay was
performed using the procedure of Clary et al. [16]. The PCR was
carried out using the following primers, derived from the c-myc hu-
man gene. A 283-bp fragment of this gene, corresponding to the P2
promoter, was ampli¢ed with primers spanning the region from nu-
cleotide 2392 (5P-TCGAGAAGGGCAGG-3P) to 2674 (5P-CCCT-
ATTCGCTCCGGATC-3P), and a 213-bp fragment of the 3P region
of the same gene was ampli¢ed with the following primers: 5P-
TTCGTTTCTTCCCCCTCCCA-3P and 5’-CCCTGCTTCTGCCAT-
TCC-3P. A typical 50-Wl reaction mixture contained 50 mM KCl, 10
mM Tris^HCl (pH 9.0), 1 mM MgCl2, 0.2 mM of each of the dNTPs,
0.2 WM of each primer, 5 Wl (1 Wg DNA) of cell lysate, and 1 Wl (3 U)
of Taq polymerase. The initial heating step was performed at 95‡C for
5 min followed by 35 cycles: 95‡C for 1 min, 55‡C for 30 s and 72‡C
for 30 s. The ¢nal cycle was followed by an extra 7 min of polymer-
ization at 72‡C before cooling to 4‡C. The reaction products (10 Wl)
were separated on a 1.5% agarose gel. The gel was stained and visu-
alized, quantitations of the bands were determined and analyzed using
Gelworks 1D Intermidiate Version 2.01 software.
2.7. RT-PCR assay
To determine c-myc, c-fos and c-jun expression, HL-60 cells were
incubated with various concentrations of salvicine for 2 h before RNA
isolation. To estimate the half-life of c-myc mRNA, HL-60 cells were
treated with 5 WM actinomycin D (Act. D) alone or 5 WM Act. D and
10 WM salvicine simultaneously for the speci¢ed times. Total RNA
was isolated from HL-60 cells using TRIzol reagent according to the
manufacturer’s instructions. RNA yields and purity were assessed by
spectrophotometric analysis. Total RNA (1 Wg) from each sample was
subjected to reverse transcription with random hexamer, dNTPs, and
10 U of M-MLV reverse transcriptase in a 20-Wl reaction volume. The
synthesized cDNA was either used immediately for PCR ampli¢cation
or stored at 320‡C for further analysis. PCR was carried out using
the following primers: 5P-CCATGGAGAAGGCTGGGG-3P (sense),
5P-CAAATGTGTCATGGATGACC-3P (antisense) for glyceralde-
hyde-3-phosphate dehydrogenase (GAPDH) [17]; 5P-CTGGTGCT-
CCATGAGGAG-3P (sense) and 5P-AGGTGATCCAGACTCT-
GAC-3P (antisense) for c-myc [18]; 5P-GGGTGAATGGAGGTGA-
TGGCAGACA-3P (sense), 5P-AGGAAGTCATCAAAGGGCTCG-
GTCT-3P (antisense) for c-fos ; 5P-AACGACCTTCTATGACGA-
TGCCCTC-3P (sense), 5P-GCGAACCCCTCCTGCTCATCTGTC-3P
(antisense) for c-jun. Each PCR reaction was performed in a 50-Wl
volume containing 2 Wl of reverse transcription reaction mixture, 50
mM KCl, 10 mM Tris^HCl (pH 9.0), 1 mM MgCl2, 0.2 mM of each
of the dNTPs, 0.2 WM of each primer, and 1 Wl (3 U) of Taq poly-
merase. Samples were denatured at 95‡C for 4 min and cycled 30
times through a 30-s denaturation step at 94‡C, a 30-s annealing
step at 57‡C, and a 30-s extension step at 72‡C. After a ¢nal PCR
Fig. 1. Chemical structure of salvicine.
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extension of 5 min at 72‡C, the samples (10 Wl) were subjected to
electrophoresis on 1.5% agarose gel in TBE. The DNA bands were
stained, visualized and analyzed as described earlier.
3. Results
3.1. Induction of DNA damage/inhibition of growth by salvicine
The growth inhibition by salvicine was evaluated using the
MTT assay. The results presented in Fig. 2 indicate that the
growth of HL-60 cells is inhibited in a concentration-depen-
dent manner after acute exposure to salvicine, with an IC50
value of approximately 4 WM. Growth inhibition by Topo II
inhibitors is thought to be a consequence of the induction of
DNA damage, resulting from disturbance of the activity of
Topo II [19,20]. DNA damage was determined by the alkaline
unwinding assay, which assessed combined single- and dou-
ble-strand breaks. As shown in Fig. 2, bulk DNA damage
could be detected at a concentration of 0.5 WM, and the
F value decreased with increasing salvicine concentration, in-
dicating that salvicine-induced DNA damage accumulated in
a concentration-dependent manner. Bulk DNA damage was
found to correspond to the antiproliferative or cytotoxic ef-
fects of salvicine in this cell line in the lower range of drug
concentration (6 5 WM). For instance, between 1 WM and
5 WM of salvicine, the growth inhibitory rate increased by
32.5% with a corresponding decrease in the F value of 0.20.
In contrast, drug concentrations in the higher range (5^10
WM) caused an insigni¢cant change in growth inhibition
(12.2%), accompanied by a decrease in the F value of 0.28.
3.2. Reversal of salvicine-induced DNA damage and secondary
DNA fragmentation
Previous work showed that formation of the Topo II inhib-
itor-induced cleavage complex reversed rapidly after drug re-
moval [2]. It is of interest to explore whether salvicine-induced
bulk DNA damage could be reversed in HL-60 cells. The
F values were determined at speci¢ed times of further incuba-
tion in drug-free medium. The results of this trial, shown in
Fig. 3, indicate that DNA damage is poorly repaired after
drug removal. The curve appears biphasic: during the ¢rst
30 min, DNA breaks partially resealed, whereas after this
initial period the breaks persisted and even increased, suggest-
ing the occurrence of secondary DNA fragmentation.
To verify the occurrence of secondary DNA fragmentation,
chromatin DNA fragmentation was measured by agarose elec-
trophoresis at various times after drug removal. As shown in
Fig. 4, at the time of removal of salvicine (lane 3) there was an
increase in high molecular DNA fragments migrating about
1 cm into the gel compared to the vehicle control (lane 2). These
fragments might result from the Topo II^DNA cleavage com-
plex induced by salvicine. The high molecular DNA fragments
disappeared gradually upon removal of the drug (lanes 4^8),
whereas the internucleosomal DNA fragment began to appear
1 h after removal of salvicine (lane 5), indicating the occur-
rence of secondary DNA fragmentation. Internucleosomal
DNA breaks are typical of cells undergoing apoptosis. The
observations reported above suggest that apoptosis occurs
subsequent to DNA damage induced by acute treatment
with salvicine. This result is consistent with reports that
Topo II inhibitors could trigger HL-60 cell apoptosis by in-
Fig. 2. Induction of DNA damage and growth inhibition by salvi-
cine in HL-60 cells. HL-60 cells were incubated at the speci¢ed con-
centrations of salvicine for 2 h. DNA damage was evaluated by the
alkaline unwinding assay, and growth inhibition was monitored us-
ing the MTT dye assay. Each value represents the mean þ S.D. of
three experiments for strand breaks and growth inhibition.
Fig. 3. Repair of salvicine-induced DNA damage in HL-60 cells.
HL-60 cells were treated for 30 min with 10 WM salvicine. The drug
was washed out with PBS twice, and cells were incubated further in
drug-free medium. At the desired times, DNA breaks were assayed
by the alkaline unwinding assay. Points represent mean þ S.D. of
three independent experiments.
Fig. 4. Secondary DNA fragmentation following salvicine treatment
on HL-60 cells. Exponentially growing cells were treated with 10
WM salvicine for 30 min. The drug was removed and cells were in-
cubated further in drug-free medium for the indicated times before
DNA extraction. Lane 1: molecular weight markers; lane 2: no
drug; lane 3: HL-60 cells that were incubated with 10 WM salvicine
for 30 min; lanes 4^8: HL-60 cells that were further incubated in
drug-free medium for 30 min, 1, 2, 3 and 4 h, respectively.
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ducing DNA fragmentation into oligonucleosome-like frag-
ments [21,22].
3.3. Salvicine-induced gene-speci¢c DNA damage
Gene-speci¢c DNA damage in HL-60 cells was analyzed by
PCR stop assay after 30 min exposure to salvicine at various
concentrations. Two fragments of the c-myc gene were
studied, one in the P2 promoter and the other in the 3P end
of the gene. Fig. 5A shows the ampli¢cation products of the
two fragments. There is no obvious modi¢cation in the am-
pli¢cation of the 3P fragment. In contrast, the ampli¢cation of
the P2 promoter fragment decreased with increasing salvicine
concentration. Quanti¢cations of the DNA bands are shown
in Fig. 5B, the P2 promoter/3P region ratio was down to 15%
of that measured in untreated cells in the presence of 10 WM
salvicine. These results show that speci¢c drug-induced cleav-
age site(s) exist(s) in the P2 promoter of the c-myc gene, in-
dicating that salvicine treatment resulted in a non-random
distribution of DNA damage. Thus, the pro¢le of salvicine-
induced DNA damage suggests that there might be heteroge-
neity in the susceptibility of discrete chromatin regions.
3.4. E¡ect of salvicine on expression of the c-myc gene
It is possible that the induction of lesions within the locus
of the c-myc gene could cause alterations in the expression of
this gene, and the c-myc gene is particularly critical for DNA
replication and for the growth of HL-60 cells. To test this
possibility, steady-state c-myc mRNA was examined by the
RT-PCR method, by comparison to a housekeeping gene,
gapdh. The e¡ect of salvicine on the expression of c-myc
was determined after 2 h of drug treatment. Fig. 6A repre-
sents the result of a typical experiment, where lane 1 is the
vehicle control, and lanes 2^5 are samples treated with various
concentrations of salvicine. Salvicine produced a speci¢c de-
crease in expression of the c-myc gene compared to the gapdh
gene. The inhibition of c-myc expression, described as [(c-myc/
gapdh)treated/(c-myc/gapdh)control]U100, is graphed in Fig. 6B.
Data from two experiments showed that the relative ampli¢-
cation of c-Myc decreased in a concentration-dependent man-
ner. The maximum inhibition reached V100% at a concen-
tration of 10 WM.
3.5. E¡ect of salvicine on the stability of c-myc mRNA
To determine whether the decrease in c-Myc transcript was
due to an altered turn-over of the mRNA, we evaluated the
in£uence of salvicine on the stability of the c-myc transcript
by measuring the rate of disappearance of the c-myc mRNA
in control and drug-treated HL-60 cells. Because of the long
half-life of gapdh [23], its transcript was analyzed simulta-
neously as an inner standard. Data from two independent
experiments were pooled and analyzed. The half-life of the
c-myc transcript was 36.1 þ 9.8 min in the absence of drug,
and 32.3 þ 2.8 min with 10 WM salvicine. There was no statis-
tically signi¢cant di¡erence in the half-lives of the c-myc
mRNA upon exposure to salvicine, as calculated using
Student’s unpaired t-test (Ps 0.05), indicating that salvicine
failed to alter the transcript stability.
Fig. 5. E¡ects of salvicine on the ampli¢cation signal generated
after PCR performed within the P2 promoter and the 3P regions of
the c-myc gene of HL-60 cells. A: Map of the c-myc gene. Exons
1^3 are represented by boxes, with the coding region hatched. Tran-
scriptional start sites are indicated by arrows. B: Lane 1: vehicle
control; lanes 2^5: samples from incubation with 1, 5, 10, 50 WM
salvicine. C: The bands in the gels of two independent experiments
were quanti¢ed and expressed as percentage of the ampli¢cation ob-
tained from undamaged DNA. Results are presented as mean þ S.D.
Fig. 6. E¡ect of salvicine on expression of the c-myc gene. A: RT-
PCR products of c-Myc and GAPDH transcripts after exposure of
HL-60 cells to various concentrations of salvicine for 2 h. Lane 1:
no drug; lanes 2^5: 1, 5, 10, 50 WM salvicine respectively. B: Quan-
ti¢cation of the DNA bands from two experiments. Results are pre-
sented as mean þ S.D.
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3.6. E¡ect of salvicine on the expression of c-fos and c-jun
Besides c-myc, c-fos and c-jun have also been found to be
within the immediate early response genes after DNA damage
in myeloid leukemia cells [24]. We examined the expression of
the two genes in HL-60 cells after treatment with salvicine at
mRNA level. As shown in Fig. 7A, treatment with salvicine
for 2 h brought out a signi¢cant increase in the expression of
both genes. Using a semi-quanti¢cation method, we observed
a concentration^response relationship for c-fos and c-jun in-
duction in HL-60 cells (Fig. 7B). The mRNA of c-fos in-
creases V1.3-fold in the presence of 1 WM salvicine, with an
increase in expression of V7.9-fold observed for 5 WM salvi-
cine, followed by a plateau between 10 WM and 50 WM. Sim-
ilar results were obtained for the case of c-jun expression.
4. Discussion
Salvicine is a newly discovered diterpenoid quinone com-
pound displaying prominent antitumor activity. Recent re-
search on the antitumor mechanism of salvicine indicates
that salvicine is a new anti-Topo II agent that inhibits Topo
II-mediated kDNA decatenation and supercoiled pBR322 re-
laxation [2]. Salvicine was found to stabilize the DNA^Topo
II cleavage complex mainly by inhibiting the DNA religation
step in the catalytic cycle, resulting in DNA double-strand
breaks [2]. Recent research on a yeast genetic system indicates
that Topo II is the primary cellular target of salvicine and that
cell killing is due to stimulation of Topo II-mediated DNA
breaks [25].
Previous studies have demonstrated a correspondence be-
tween double-strand breaks of DNA and the cytotoxicity ef-
fects of some DNA Topo poisons [26]. Ryan et al. [7] reported
that double-strand breaks in nascent DNA are closely related
to the activity of camptothecin against SV-40-transformed
skin ¢broblast. However, it has long been evident that induc-
tion of DNA breaks throughout the genome is associated with
cytotoxicity or antiproliferative activity of Topo II inhibitors
[8,27]. The results in the present study demonstrated a close
relationship between DNA bulk damage and cytotoxicity in
the lower range of concentrations of salvicine in HL-60 cells.
The DNA damage could be partially repaired, but apoptosis
was ultimately induced, suggesting that the early DNA break
triggers the process of cell apoptosis. It is of interest that
DNA damage did not parallel growth inhibition at higher
salvicine concentrations (s 5 WM). This lack of correspond-
ence was probably due to two reasons. First, bulk DNA dam-
age that was detected after 2 h incubation was a combination
of direct topoisomerase II-mediated damage and secondary
DNA fragmentation. Second, it is possible that random
DNA damage was detected by the alkaline unwinding assay,
whereas only breaks which are induced at genomic sites in-
volved in proliferating functions could be responsible for com-
promised cell growth and/or loss of viability.
It is well known that Topo II poisons induce preferential
DNA breaks within the c-myc locus, and further research has
demonstrated that VP16 and AMSA induce prominent Topo
II-mediated cleavage in the P2 promoter in a cell-free system
[28]. In this study, a PCR stop assay was utilized as an e¡ec-
tive and sensitive method for measuring whether salvicine
induced preferential breaks in some regions of c-myc. The
overall sensitivity of this assay is re£ected in its capacity to
detect region-speci¢c damage produced by 1 WM salvicine in
the locus of the P2 promoter. The PCR stop assay provides an
additional advantage in being able to detect a more precise
localization of the cleavage sites. We have shown that there
was preferential damage in the P2 promoter of the c-myc gene,
in comparison to the 3P region of the same gene. The cleavage
patterns mediated by Topo II poisons observed in living cells
are thought to be determined by two factors: chromatin struc-
ture and speci¢c DNA sequence. Although we did not check
all regions of the c-myc gene, our results provide a clue that
chromatin structure might be more essential for the DNA
cleavage speci¢city of salvicine. Since c-myc is an active
gene in HL-60 cells and the P2 promoter is a strong promoter,
its chromatin structure might be more accessible to Topo II.
Because DNA synthesis and transcription contribute to the
formation of permanent Topo II-associated DNA breaks,
DNA breaks that occur within the locus of some active genes
might enhance the drug activity. This result proves our hy-
pothesis that some ‘critical’ DNA fragments (e.g. c-myc) have
an increased susceptibility to salvicine. On the other hand,
damage to the P2 promoter of the c-myc gene did not parallel
growth inhibition in HL-60 cells, suggesting that DNA breaks
at other sites of the c-myc locus (e.g. P1 promoter) or another
critical gene locus might exist. Improved knowledge on the
DNA speci¢city of salvicine may have a profound in£uence
on the design and development of novel Topo II-based ther-
apeutics or regimens.
Since salvicine-mediated DNA breaks, especially at the crit-
Fig. 7. E¡ect of salvicine on the expression of c-fos and c-jun. A:
RT-PCR products of c-fos, c-jun and gapdh transcripts after expo-
sure of HL-60 cells for 2 h to various concentrations of salvicine.
Lane 1: no drug; lanes 2^5: 1, 5, 10, 50 WM salvicine, respectively.
B: Quanti¢cation of the DNA bands from two experiments. Results
are presented as mean þ S.D.
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ical gene locus, appear to be an early signal causing cell death,
we wished to know what happened in the interval between
complex formation and the presence of internucleosomal
DNA ladders. To determine if damage in the c-myc gene locus
leads to an alteration in the expression of this gene, c-myc
mRNA was examined at transcriptional and post-transcrip-
tional levels. The results showed that the stability of mRNA
was not responsible for the down-regulation of c-myc expres-
sion. We postulated that down-regulated steady levels of
c-myc should result from DNA breaks in the P2 promoter.
Clary et al. [16] reported that Topo II-mediated DNA breaks
within the P2 promoter by AMSA are probably responsible
for the down-regulation of the c-myc gene, which in turn is
involved in the apoptosis pathway in K-562 cells. More re-
cently, a triple helix-forming oligonucleotide (TFO) targeted
to a homopurine-homopyrimidine sequence in the P2 pro-
moter of the c-myc gene was synthesized. Incubation of leu-
kemia or lymphoma cells with TFO reduced c-myc RNA and
protein levels and induced cell death by apoptosis [29,30].
Combining past results with those presented here, we consider
that the P2 promoter should be further studied in antitumor
research and that inactivation of the P2 promoter might pro-
vide a new strategy for tumor therapy.
On the other hand, reduction in the expression of c-myc by
salvicine did not correspond closely to growth inhibition. It is
possible that Topo II-mediated DNA damage in the c-myc
and other genes may induce replication-associated damage
which could be lethal to the cells independent of the e¡ects
on the transcription and c-Myc expression. Our experimental
results also showed that other related genes might be involved
in the signaling pathway leading to apoptosis. It has been
reported that Topo II inhibitor-induced apoptosis is accom-
panied by the up-regulation of c-fos and c-jun genes in human
myeloid leukemia cells [31]. In the present study, we observed
that salvicine activated the transcription of the protoonco-
genes c-fos and c-jun in HL-60 cells, and this induction was
accompanied by subsequent formation of internucleosomal
DNA ladders. However, it is still unknown whether up-regu-
lation of their mRNA is the result of DNA damage. A better
understanding of the mechanism will be helpful for further
development of salvicine-like analogues. The Jun-family pro-
teins are known as transcription factors that form homo-
dimers or heterodimers with Fos-family proteins, referred to
as activator protein-1 (AP-1). AP-1 may control the expres-
sion of the gene programs ultimately responsible for the trig-
gering and execution of speci¢c cellular processes, such as
proliferation, di¡erentiation and cell death [32]. Our results
suggest that AP-1 may be connected to the transcriptional
activation of other downstream DNA damage-inducible genes
in the signaling pathway leading to apoptosis.
In summary, the new Topo II inhibitor salvicine induced
DNA damage and early DNA breaks and triggered the pro-
cess of apoptosis in HL-60 cells. Salvicine preferentially
caused DNA breaks in the P2 promoter of the c-myc gene,
thereafter inhibiting the expression of c-myc. Salvicine also
induced a marked increase in the transcription of c-fos and
c-jun. These results suppose that DNA damage, especially in
some gene-speci¢c regions such as the P2 promoter of c-myc,
is an early signal leading to salvicine-mediated HL-60 cell
apoptosis. We further suggest that inactivation of the P2 pro-
moter is a valid approach to inhibit c-myc expression and
tumor cell growth, with potential to be a new target for leu-
kemia and lymphoma.
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